Retatrutide
LY3437943
Retatrutide is a novel triple hormone receptor agonist that simultaneously activates GLP-1, GIP, and glucagon receptors for superior metabolic effects. This innovative approach produces enhanced appetite suppression, improved insulin sensitivity, and increased energy expenditure, potentially delivering 20-25% weight loss in clinical trials.
Technical Specifications
Molecular Information
Amino Acid Sequence
Triple receptor agonist peptide - proprietary sequence (LY3437943)Storage & Handling
Store pre-filled pens refrigerated at 2-8°C. Do not freeze or shake. Use within 56 days of first use. Protect from light and heat sources.
STORAGE REQUIREMENTS
Medical Disclaimer
Retatrutide is currently in Phase 3 clinical trials and is not yet FDA approved. This information is for educational purposes only and should not replace medical advice. Consult with healthcare providers familiar with investigational therapies for personalized guidance. Side effects and contraindications are based on available clinical trial data.